- Sweden
- /
- Medical Equipment
- /
- OM:ADDV A
ADDvise Group Second Quarter 2025 Earnings: kr0.14 loss per share (vs kr0.15 profit in 2Q 2024)
ADDvise Group (STO:ADDV A) Second Quarter 2025 Results
Key Financial Results
- Revenue: kr396.9m (down 4.1% from 2Q 2024).
- Net loss: kr82.8m (down by 378% from kr29.8m profit in 2Q 2024).
- kr0.14 loss per share (down from kr0.15 profit in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
ADDvise Group Earnings Insights
Looking ahead, revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Medical Equipment industry in Sweden.
Performance of the Swedish Medical Equipment industry.
The company's shares are up 3.7% from a week ago.
Risk Analysis
It is worth noting though that we have found 4 warning signs for ADDvise Group (2 are a bit unpleasant!) that you need to take into consideration.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:ADDV A
ADDvise Group
Supplies medical devices, equipment, and consumables to public and private laboratories and research facilities, healthcare, and pharmaceuticals in North America, Europe, South America, Sweden, and internationally.
Undervalued slight.
Market Insights
Community Narratives
